Mycobacterium abscessus disease in lung transplant recipients: Diagnosis and management

Satish Chandrashekaran, Patricio Escalante, Cassie Kennedy

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Mycobacterium abscessus complex (MAbsC) disease in lung transplant recipients is increasingly being recognized as an important cause of graft function decline and suboptimal outcomes. Lung transplant recipients appear to be at the highest risk of MAbsC among solid organ transplant recipients, as they have more intense immunosuppression, and the organisms preferentially inhabit the lungs. MAbsC is the most resistant species of rapidly growing mycobacteria and difficult to treat, causing considerable mortality and morbidity in immunocompetent and immunosuppressed patients. Herein we describe the risk factors, epidemiology, clinical features, diagnostics, and treatment strategies of MAbsC in lung transplant candidates and recipients.

Original languageEnglish (US)
Pages (from-to)10-18
Number of pages9
JournalJournal of Clinical Tuberculosis and Other Mycobacterial Diseases
Volume9
DOIs
StatePublished - Dec 1 2017

Fingerprint

Mycobacterium
Lung Diseases
Lung
Transplants
Immunosuppression
Epidemiology
Transplant Recipients
Morbidity
Mortality
Therapeutics

Keywords

  • Lung infection
  • Lung transplant
  • Mycobacterial abscessus complex

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{246c7e10bb6d4b4490d09fbdc5e2dc29,
title = "Mycobacterium abscessus disease in lung transplant recipients: Diagnosis and management",
abstract = "Mycobacterium abscessus complex (MAbsC) disease in lung transplant recipients is increasingly being recognized as an important cause of graft function decline and suboptimal outcomes. Lung transplant recipients appear to be at the highest risk of MAbsC among solid organ transplant recipients, as they have more intense immunosuppression, and the organisms preferentially inhabit the lungs. MAbsC is the most resistant species of rapidly growing mycobacteria and difficult to treat, causing considerable mortality and morbidity in immunocompetent and immunosuppressed patients. Herein we describe the risk factors, epidemiology, clinical features, diagnostics, and treatment strategies of MAbsC in lung transplant candidates and recipients.",
keywords = "Lung infection, Lung transplant, Mycobacterial abscessus complex",
author = "Satish Chandrashekaran and Patricio Escalante and Cassie Kennedy",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.jctube.2017.08.002",
language = "English (US)",
volume = "9",
pages = "10--18",
journal = "Journal of Clinical Tuberculosis and Other Mycobacterial Diseases",
issn = "2405-5794",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Mycobacterium abscessus disease in lung transplant recipients

T2 - Diagnosis and management

AU - Chandrashekaran, Satish

AU - Escalante, Patricio

AU - Kennedy, Cassie

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Mycobacterium abscessus complex (MAbsC) disease in lung transplant recipients is increasingly being recognized as an important cause of graft function decline and suboptimal outcomes. Lung transplant recipients appear to be at the highest risk of MAbsC among solid organ transplant recipients, as they have more intense immunosuppression, and the organisms preferentially inhabit the lungs. MAbsC is the most resistant species of rapidly growing mycobacteria and difficult to treat, causing considerable mortality and morbidity in immunocompetent and immunosuppressed patients. Herein we describe the risk factors, epidemiology, clinical features, diagnostics, and treatment strategies of MAbsC in lung transplant candidates and recipients.

AB - Mycobacterium abscessus complex (MAbsC) disease in lung transplant recipients is increasingly being recognized as an important cause of graft function decline and suboptimal outcomes. Lung transplant recipients appear to be at the highest risk of MAbsC among solid organ transplant recipients, as they have more intense immunosuppression, and the organisms preferentially inhabit the lungs. MAbsC is the most resistant species of rapidly growing mycobacteria and difficult to treat, causing considerable mortality and morbidity in immunocompetent and immunosuppressed patients. Herein we describe the risk factors, epidemiology, clinical features, diagnostics, and treatment strategies of MAbsC in lung transplant candidates and recipients.

KW - Lung infection

KW - Lung transplant

KW - Mycobacterial abscessus complex

UR - http://www.scopus.com/inward/record.url?scp=85028763948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028763948&partnerID=8YFLogxK

U2 - 10.1016/j.jctube.2017.08.002

DO - 10.1016/j.jctube.2017.08.002

M3 - Review article

AN - SCOPUS:85028763948

VL - 9

SP - 10

EP - 18

JO - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

JF - Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

SN - 2405-5794

ER -